Brazil to produce AstraZeneca’s experimental coronavirus vaccine

British drug-maker already carrying out large-scale, mid-stage human trials

Marcelo Rochabrun
Sao Paulo
Saturday 27 June 2020 17:46
Comments
Health official said country will initially produce some 30 million doses of the vaccine, half by December and half by January of next year
Health official said country will initially produce some 30 million doses of the vaccine, half by December and half by January of next year

Brazil announced on Saturday that it had signed a $127m (£102m) agreement to start producing locally an experimental vaccine developed by AstraZeneca that has shown promise to fight the Covid-19 pandemic.

The AstraZeneca vaccine is considered the world’s leading candidate and most advanced in terms of development to obtain licensure and become an official vaccine against the disease, according to the World Health Organisation.

The British drug-maker is already carrying out large-scale, mid-stage human trials of the vaccine, which was developed by researchers at Oxford University.

Elcio Franco, Brazil’s number two public health official, said in a press conference that the country will initially produce some 30 million doses of the vaccine, half by December and half by January of next year.

Mr Franco said Brazil is paying for the vaccine but is aware of the risk, in case the vaccine does not pass all necessary licensure requirements or another vaccine obtains approval faster.

The vaccine will be produced by Brazil’s Fundação Osvaldo Cruz, also known as Fiocruz, the country’s leading public health organisation, Mr Franco said.

Brazil is the world’s second most affected country by the coronavirus pandemic, with more than 1.2 million confirmed cases as of Friday and more than 55,000 deaths.

Right-wing president Jair Bolsonaro has been widely criticised for this response to the pandemic. He has dismissed the severity of the disease and has shown indifference to the rising death toll while also pushing treatment using an unproven anti-malaria drug.

Reuters

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in